Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Dahut Website

William L. Dahut, M.D.

Selected Publications

1)  Madan RA, Shah AA, Dahut WL.
Is it time to reevaluate definitive therapy in prostate cancer?.
J. Natl. Cancer Inst. 105: 683-5, 2013.
[Journal]
2)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
[Journal]
3)  Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
BJU Int. [Epub ahead of print], 2013.
[Journal]
4)  Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity.
Clin Genitourin Cancer. 11: 229-37, 2013.
[Journal]
5)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
[Journal]
6)  Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL.
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate Cancer Prostatic Dis. [Epub ahead of print], 2012.
[Journal]
7)  Gulley JL, Leitman SF, Dahut W, Schlom J.
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
J. Natl. Cancer Inst. 104: 1106; author reply 1109-12, 2012.
[Journal]
8)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
[Journal]
9)  Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL.
The Kinetics and Reproducibility of 18F-Sodium Fluoride for Oncology Using Current PET Camera Technology.
J. Nucl. Med. 53: 1175-84, 2012.
[Journal]
10)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 9/9/2013.